Nutcracker Therapeutics Demonstrates Enhanced Activity of B Cell Lymphoma Candidate NTX-472 at the 2024 ASCO Annual Meeting
Nutcracker Therapeutics to Unveil New Drug Candidate NTX-472 at ASCO 2024 and Participate in the Sachs Oncology Innovation Forum
In a world overrun by innovative biotechs, be a Mammoth Biosciences. Or a Nutcracker Therapeutics. Or Viking Therapeutics or Centessa Pharmaceuticals. I could go on and on and on with creative names of companies in this industry that are vibrant, fun and eye-catching. But most importantly, they make you overlook the potential scientific language barrier, the potential to not exactly understand what the company is doing at all, and make you want to learn more anyway.
Nutcracker Therapeutics Demonstrates Enhanced Functional Activity of Prostate Cancer Candidate NTX-470 at the 2024 AACR Annual Meeting
Nutcracker Therapeutics to Present Data on mRNA Drug Candidate
Nutcracker Named Industry Veteran Samuel Deutsch as Chief Scientific Officer
Nutcracker Demonstrates Anti-tumor Responses of Preclinical mRNA Drug Candidates
Nutcracker Therapeutics to Present Data for mRNA Drug Candidates at SITC 2023
Big money RNA biotech Nutcracker Therapeutics laid off 12 employees, according to two sources familiar with the decision.
Nutcracker Therapeutics appoints Cynthia Collins, biopharma veteran and former Editas Medicine CEO, to board of directors